Literature DB >> 30948431

Survivin at a glance.

Sally P Wheatley1, Dario C Altieri2.   

Abstract

Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. In this Cell Science at a Glance article and accompanying poster, we summarise our knowledge of survivin 21 years on from its initial discovery. We describe the structure, expression and function of survivin, highlight its interactome and conclude by describing anti-survivin strategies being trialled.
© 2019. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Apoptosis; BIRC5; Cancer; Mitosis; Survivin

Mesh:

Substances:

Year:  2019        PMID: 30948431      PMCID: PMC6467487          DOI: 10.1242/jcs.223826

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  104 in total

1.  Analysis of human transcriptomes.

Authors:  V E Velculescu; S L Madden; L Zhang; A E Lash; J Yu; C Rago; A Lal; C J Wang; G A Beaudry; K M Ciriello; B P Cook; M R Dufault; A T Ferguson; Y Gao; T C He; H Hermeking; S K Hiraldo; P M Hwang; M A Lopez; H F Luderer; B Mathews; J M Petroziello; K Polyak; L Zawel; K W Kinzler
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement.

Authors:  M A Verdecia; H Huang; E Dutil; D A Kaiser; T Hunter; J P Noel
Journal:  Nat Struct Biol       Date:  2000-07

3.  HBXIP functions as a cofactor of survivin in apoptosis suppression.

Authors:  Hiroyuki Marusawa; Shu-Ichi Matsuzawa; Kate Welsh; Hua Zou; Robert Armstrong; Ingo Tamm; John C Reed
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

4.  Increased p21(ras) activity in human fibroblasts transduced with survivin enhances cell proliferation.

Authors:  Achim Temme; Petra Diestelkoetter-Bachert; Marc Schmitz; Agnieszka Morgenroth; Bernd Weigle; Michael A Rieger; Andrea Kiessling; E Peter Rieber
Journal:  Biochem Biophys Res Commun       Date:  2005-02-18       Impact factor: 3.575

5.  BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.

Authors:  J Hagenbuchner; A V Kuznetsov; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

6.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype.

Authors:  A G Uren; L Wong; M Pakusch; K J Fowler; F J Burrows; D L Vaux; K H Choo
Journal:  Curr Biol       Date:  2000-11-02       Impact factor: 10.834

7.  Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo.

Authors:  Robert A Fenstermaker; Sheila A Figel; Jingxin Qiu; Tara A Barone; Sanam S Dharma; Evan K Winograd; Phillip M Galbo; Laura M Wiltsie; Michael J Ciesielski
Journal:  Clin Cancer Res       Date:  2018-03-14       Impact factor: 12.531

8.  Endogenous tumor suppression mediated by PTEN involves survivin gene silencing.

Authors:  Minakshi Guha; Janet Plescia; Irwin Leav; Jing Li; Lucia R Languino; Dario C Altieri
Journal:  Cancer Res       Date:  2009-05-26       Impact factor: 12.701

Review 9.  Survivin splice variants and their diagnostic significance.

Authors:  Nand K Sah; Chandrabhan Seniya
Journal:  Tumour Biol       Date:  2015-08-06

10.  The N-terminus of survivin is a mitochondrial-targeting sequence and Src regulator.

Authors:  Lucia Dunajová; Emily Cash; Robert Markus; Sophie Rochette; Amelia R Townley; Sally P Wheatley
Journal:  J Cell Sci       Date:  2016-05-31       Impact factor: 5.285

View more
  87 in total

1.  Inhibition of Wnt signaling by Frizzled7 antibody-coated nanoshells sensitizes triple-negative breast cancer cells to the autophagy regulator chloroquine.

Authors:  Jianxin Wang; Megan N Dang; Emily S Day
Journal:  Nano Res       Date:  2020-04-25       Impact factor: 8.897

2.  Competing Endogenous RNA (ceRNA) Network Analysis of Autophagy-Related Genes in Hepatocellular Carcinoma.

Authors:  Chenyu Yang; Qian Dong; Chengzhan Zhu; Yixiu Wang; Weijie Xue; Yuwei Xie
Journal:  Pharmgenomics Pers Med       Date:  2020-10-13

Review 3.  Molecular determinants of the meiotic arrests in mammalian oocytes at different stages of maturation.

Authors:  Saffet Ozturk
Journal:  Cell Cycle       Date:  2022-01-24       Impact factor: 4.534

Review 4.  Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators.

Authors:  Mark A Klein; John M Denu
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

5.  A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.

Authors:  Yuan-Hung Lo; Kevin S Kolahi; Yuhong Du; Chiung-Ying Chang; Andrey Krokhotin; Ajay Nair; Walter D Sobba; Kasper Karlsson; Sunny J Jones; Teri A Longacre; Amanda T Mah; Bahar Tercan; Alexandra Sockell; Hang Xu; Jose A Seoane; Jin Chen; Ilya Shmulevich; Jonathan S Weissman; Christina Curtis; Andrea Califano; Haian Fu; Gerald R Crabtree; Calvin J Kuo
Journal:  Cancer Discov       Date:  2021-01-15       Impact factor: 39.397

6.  Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses.

Authors:  Yimin Li; Shun Lu; Shubin Wang; Xinhao Peng; Jinyi Lang
Journal:  J Transl Med       Date:  2021-05-24       Impact factor: 5.531

7.  Immune infiltration and a ferroptosis-related gene signature for predicting the prognosis of patients with cholangiocarcinoma.

Authors:  Zhijian Wang; Xuenuo Chen; Zheng Jiang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

8.  Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents.

Authors:  Qing Zhou; Xiotian Sun; Nicolas Pasquier; Parvaneh Jefferson; Trang T T Nguyen; Markus D Siegelin; James M Angelastro; Lloyd A Greene
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

9.  Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.

Authors:  Nina Oparina; Malin C Erlandsson; Anna Fäldt Beding; Toshima Parris; Khalil Helou; Per Karlsson; Zakaria Einbeigi; Maria I Bokarewa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

Review 10.  Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.

Authors:  Ban Qi Tay; Quentin Wright; Rahul Ladwa; Christopher Perry; Graham Leggatt; Fiona Simpson; James W Wells; Benedict J Panizza; Ian H Frazer; Jazmina L G Cruz
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.